Gaucher Disease: Clinical, Biological and Therapeutic Aspects.
Dandana A, Ben Khelifa S, Chahed H, Miled A, Ferchichi S.
Pathobiology. 2016;83(1):13-23. doi: 10.1159/000440865. Epub 2015 Nov 21.
Lipid storage disease.
Thompson IL, Moloney WC.
Blood. 1966 Jan;27(1):49-56.
Drug-induced phospholipidosis.
Anderson N, Borlak J.
FEBS Lett. 2006 Oct 9;580(23):5533-40. doi: 10.1016/j.febslet.2006.08.061. Epub 2006 Sep 5.
Neutral lipid storage disease with ichthyosis and fatty liver.
Inamadar A, Inamadar A.
BMJ Case Rep. 2024 May 15;17(5):e259962. doi: 10.1136/bcr-2024-259962.
Lysosomal lipid storage diseases.
Schulze H, Sandhoff K.
Cold Spring Harb Perspect Biol. 2011 Jun 1;3(6):a004804. doi: 10.1101/cshperspect.a004804.
SCA34 caused by ELOVL4 L168F mutation is a lysosomal lipid storage disease sharing pathology features with neuronal ceroid lipofuscinosis and peroxisomal disorders.
Ellezam B, Kaseka ML, Nguyen DK, Michaud J.
Acta Neuropathol. 2023 Aug;146(2):337-352. doi: 10.1007/s00401-023-02582-0. Epub 2023 May 15.
The liver in lipid storage disease: biochemical basis of pathogenesis and clinical features.
Brady RO, James SP, Barranger JA.
Prog Liver Dis. 1982;7:331-46.
Seeking a unique lipid signature predicting cardiovascular disease risk.
Brown JM, Hazen SL.
Circulation. 2014 May 6;129(18):1799-803. doi: 10.1161/CIRCULATIONAHA.114.009224. Epub 2014 Mar 12.
Lipolysis in adipocytes.
Ahmadian M, Wang Y, Sul HS.
Int J Biochem Cell Biol. 2010 May;42(5):555-9. doi: 10.1016/j.biocel.2009.12.009. Epub 2009 Dec 16.
Enzymic defects in lipid-storage diseases.
Brady RO.
Biochem J. 1970 Apr;117(2):8P-10P. doi: 10.1042/bj1170008p.
